Jonathan Brett1, Donovan T Maust2,3,4, Zach Bouck5, Rosalinda V Ignacio2,3,4, Graham Mecredy6, Eve A Kerr2,4,7, Sacha Bhatia5, Adam G Elshaug8, Sallie A Pearson1,8. 1. Medicines Policy Research Unit, Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia. 2. Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan. 3. Department of Psychiatry, University of Michigan, Ann Arbor, Michigan. 4. Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan. 5. Institute for Health Systems Solutions and Virtual Care, Women's College Hospital, Toronto, Ontario, Canada. 6. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. 7. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 8. Menzies Centre for Health Policy, School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
Abstract
OBJECTIVES: To detail annual trends in benzodiazepine incidence and prevalence in older adults between 2010 and 2016 in three countries. DESIGN: Observational multicountry cohort study with harmonized study protocol. SETTING: The United States (veteran population); Ontario, Canada; and Australia. PARTICIPANTS: All people aged 65 and older (8,270,000 people). MEASUREMENTS: Annual incidence and prevalence of benzodiazepine use stratified according to age group (65-74, 75-84, ≥85) and sex. We performed multiple regression analyses to assess whether rates of incident and prevalent use changed significantly over time. RESULTS: Over the study period, we observed a significant decrease in incident benzodiazepine use in the United States (2.6% to 1.7%) and Ontario (6.0% to 4.4%) but not Australia (7.0% to 6.7%). We found significant declines in prevalent use in all countries (United States: 9.2% to 7.3%; Ontario: 18.2% to 13.4%; Australia: 20.2% to 16.8%). Although incidence and prevalence increased with age in Ontario and Australia, they decreased with age in the United States. Incidence and prevalence were higher in women in all countries. CONCLUSION: Consistent with other international studies, there have been small but significant reductions in the incidence and prevalence of benzodiazepine use in older adults in all three countries, with the exception of incidence in Australia, although use remains inappropriately high-particularly in those aged 85 and older-which warrants further attention from clinicians and policy-makers.
OBJECTIVES: To detail annual trends in benzodiazepine incidence and prevalence in older adults between 2010 and 2016 in three countries. DESIGN: Observational multicountry cohort study with harmonized study protocol. SETTING: The United States (veteran population); Ontario, Canada; and Australia. PARTICIPANTS: All people aged 65 and older (8,270,000 people). MEASUREMENTS: Annual incidence and prevalence of benzodiazepine use stratified according to age group (65-74, 75-84, ≥85) and sex. We performed multiple regression analyses to assess whether rates of incident and prevalent use changed significantly over time. RESULTS: Over the study period, we observed a significant decrease in incident benzodiazepine use in the United States (2.6% to 1.7%) and Ontario (6.0% to 4.4%) but not Australia (7.0% to 6.7%). We found significant declines in prevalent use in all countries (United States: 9.2% to 7.3%; Ontario: 18.2% to 13.4%; Australia: 20.2% to 16.8%). Although incidence and prevalence increased with age in Ontario and Australia, they decreased with age in the United States. Incidence and prevalence were higher in women in all countries. CONCLUSION: Consistent with other international studies, there have been small but significant reductions in the incidence and prevalence of benzodiazepine use in older adults in all three countries, with the exception of incidence in Australia, although use remains inappropriately high-particularly in those aged 85 and older-which warrants further attention from clinicians and policy-makers.
Authors: Donovan T Maust; Frederic C Blow; Ilse R Wiechers; Helen C Kales; Steven C Marcus Journal: J Clin Psychiatry Date: 2017-04 Impact factor: 4.384
Authors: Andrea Iaboni; Susan E Bronskill; Katelyn B Reynolds; Xuesong Wang; Paula A Rochon; Nathan Herrmann; Alastair J Flint Journal: Drugs Aging Date: 2016-07 Impact factor: 3.923
Authors: Anita K Wagner; Fang Zhang; Stephen B Soumerai; Alexander M Walker; Jerry H Gurwitz; Robert J Glynn; Dennis Ross-Degnan Journal: Arch Intern Med Date: 2004-07-26
Authors: Ruth Ann Marrie; John D Fisk; Randy Walld; James M Bolton; Jitender Sareen; Scott B Patten; Alexander Singer; Lisa M Lix; Carol A Hitchon; Renée El-Gabalawy; Alan Katz; James J Marriott; Charles N Bernstein Journal: Front Neurol Date: 2022-04-14 Impact factor: 4.086
Authors: James Henderson; Zachary Bouck; Rob Holleman; Cherry Chu; Mandi L Klamerus; Robin Santiago; R Sacha Bhatia; Eve A Kerr Journal: JAMA Intern Med Date: 2020-04-01 Impact factor: 21.873
Authors: Derek D Satre; Matthew E Hirschtritt; Michael J Silverberg; Stacy A Sterling Journal: Am J Geriatr Psychiatry Date: 2020-04-22 Impact factor: 4.105
Authors: James Shaw; Andrea L Murphy; Justin P Turner; David M Gardner; James L Silvius; Zachary Bouck; Dara Gordon; Cara Tannenbaum Journal: Healthc Policy Date: 2019-05
Authors: Donovan T Maust; H Myra Kim; Ilse R Wiechers; Rosalinda V Ignacio; Amy S B Bohnert; Frederic C Blow Journal: J Am Geriatr Soc Date: 2020-09-20 Impact factor: 5.562
Authors: Rajan Sacha Bhatia; Dennis T Ko; Cherry Chu; Ruth Croxford; Zachary Bouck; Tharmegan Tharmaratnam; Paul Dorian; Heather Ross; Peter C Austin; Kaveh Shojania; Shaun G Goodman Journal: CJC Open Date: 2021-02-09